This trial is active, not recruiting.

Conditions angioid streaks, choroidal neovascularization
Treatment intravitreal bevacizumab
Phase phase 3
Sponsor Asociación para Evitar la Ceguera en México
Start date November 2005
End date May 2006
Trial identifier NCT00599820, APEC 010


Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

time frame:
Fluoresceine Angiography
time frame:
Optical Coherence Tomography
time frame:

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Clinical diagnosis of Angioid Streaks - Choroidal neovascularization associated - Untreated patients or patients treated once with PDT Exclusion Criteria: - Ocular surgery excepting uncomplicated phacoemulsification - Glaucoma or any other ocular pathology

Additional Information

Official title OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab
Principal investigator Adriana Solís-Vivanco, MD
Description A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
Trial information was received from ClinicalTrials.gov and was last updated in January 2008.
Information provided to ClinicalTrials.gov by Asociación para Evitar la Ceguera en México.